Advances in chemotherapy for HER2-negative metastatic breast cancer

被引:3
|
作者
Mukai, Hirofumi [1 ]
Ito, Mayuko [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
关键词
Breast cancer; chemotherapy; quality of life (QOL); survival;
D O I
10.21037/cco.2018.06.01
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [32] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [33] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [36] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
  • [37] Targeted Therapy of HER2-Negative Breast Cancer
    Schuetz, Florian
    Domschke, Christoph
    Schneeweiss, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (03) : 118 - 121
  • [38] Adjuvant capecitabine for HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (07): : E375 - E375
  • [39] Anthracyclines in the treatment of HER2-negative breast cancer
    Paik, Soonmyung
    Taniyama, Yusuke
    Geyer, Charles E., Jr.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01): : 2 - 4
  • [40] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821